Gene · 2931
GSK3A: glycogen synthase kinase 3 alpha
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. GSK3A: glycogen synthase kinase 3 alpha. Genes, record 2931. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/2931
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P49840 | Glycogen synthase kinase-3 alpha | 483 | 2 | Ensembl, GeneID, HGNC |
Source UniProt
Patents67
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 552 | P49840 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 388 | P49840 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 388 | P49840 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 552 | P49840 | Espacenet |
| US 11892452 B2 | 2024-02-06 | 131 | P49840 | Espacenet |
| JP 2023123507 A | 2023-09-05 | 11 | P49840 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 4727 | P49840 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 8099 | P49840 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 35587 | P49840 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 35589 | P49840 | Espacenet |
1 to 10 of 67
See all 67 patentsDrugs5
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AZD-1080 | CHEMBL1969664 | Glycogen synthase kinase-3 inhibitor | INHIBITOR | ChEMBL |
| LITHIUM CARBONATE | CHEMBL1200826 | Glycogen synthase kinase-3 inhibitor | INHIBITOR | ChEMBL |
| LITHIUM CITRATE | CHEMBL2103738 | Glycogen synthase kinase-3 inhibitor | INHIBITOR | ChEMBL |
| LITHIUM CITRATE ANHYDROUS | CHEMBL1201170 | Glycogen synthase kinase-3 inhibitor | INHIBITOR | ChEMBL |
| LY-2090314 | CHEMBL362558 | Glycogen synthase kinase-3 alpha inhibitor | INHIBITOR | ChEMBL |
Trials90
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07540338 | LITHIUM CARBONATE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06789783 | LITHIUM CARBONATE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06424613 | LITHIUM CARBONATE | ClinicalTrials.gov | ||
| NCT06184581 | LITHIUM CARBONATE | PHASE4 | ClinicalTrials.gov | |
| NCT06008249 | LITHIUM CARBONATE | PHASE3 | ClinicalTrials.gov | |
| NCT05973786 | LITHIUM CARBONATE | PHASE3 | ClinicalTrials.gov | |
| NCT05923476 | LITHIUM CARBONATE | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT05913947 | LITHIUM CARBONATE | PHASE4 | ClinicalTrials.gov | |
| NCT05814640 | LITHIUM CARBONATE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05618587 | LITHIUM CARBONATE | PHASE2 | 2025-03-05 | ClinicalTrials.gov |
1 to 10 of 90
See all 90 trialsNIH grants2,118
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | GSK3A papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 28 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 9 | 2025 |
| R01HL133290 | Signaling Mechanisms Governing Myocardial Fibrosis in Diseased Heart | 8 | 2025 |
| P30CA060553 | The Robert H. Lurie Comprehensive Cancer Center | 6 | 2025 |
| R01HL143074 | Novel Mechanisms of Cardiac Function and Dysfunction | 6 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 5 | 2025 |
| P30DK020572 | Michigan Diabetes Research Center (MDRC) | 5 | 2025 |
| P30DK036836 | Diabetes Research Center | 5 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 4 | 2025 |
| P30CA016086 | Cancer Center Support Grant | 4 | 2025 |
1 to 10 of 2,118Source NIH's project files
See all 2,118 nih grantsPapers2,889
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| CREB1 and GSK3 Isoforms as Potential Adaptive Signaling Nodes in PI3K/Akt/mTOR Inhibitor Treated Philadelphia Chromosome-Positive B-ALL. | Int J Mol Sci | 2026 | 42794727 | PubTator, text mining | PubMed |
| Deep learning-assisted virtual screening of a large chemical library for selective GSK3β inhibitors. | Mol Divers | 2026 | 42584522 | PubTator, text mining | PubMed |
| Navigating the Complexity: A Comprehensive Review of GSK-3 Inhibition in Regenerative Medicine. | Med Res Rev | 2026 | 42559793 | PubTator, text mining | PubMed |
| A universal 6iL/E4 culture system for deriving and maintaining embryonic stem cells across mammalian species. | Cell Res | 2026 | 42443522 | PubTator, text mining | PubMed |
| Integrated Proteomic and Phosphoproteomic Profiling Reveals Mechanisms of Bisphenol A Induced Placental Toxicity. | Chem Res Toxicol | 2026 | 42440269 | PubTator, text mining | PubMed |
| Integrated machine learning, molecular docking, and molecular dynamics simulations for in silico identification of GSK3β inhibitors for Alzheimer's disease. | Sci Rep | 2026 | 42365084 | PubTator, text mining | PubMed |
| Rosmarinic acid as a potential GSK3β inhibitor for autism spectrum disorder: insights from an integrative in silico study. | In Silico Pharmacol | 2026 | 42064451 | PubTator, text mining | PubMed |
| Dual-target antioxidant potential of benzimidazole-based thiazine and N-tosylated analogues: computational insights into human 11β-HSD1 and Leishmania GSK-3α inhibition. | Comput Biol Med | 2026 | 42061289 | PubTator, text mining | PubMed |
| GSK3α functions as a stemness checkpoint across multiple stem cell states. | Cell Res | 2026 | 41951855 | PubTator, text mining | PubMed |
| Wnt-dependent Frizzled clustering is required for Dishevelled phosphorylation but insufficient for β-catenin stabilization. | Sci Signal | 2026 | 41945658 | PubTator, text mining | PubMed |
1 to 10 of 2,889
See all 2,889 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/2931
GET https://conductscience.org/api/genes/v1/2931/patents?page=2